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Abstract
A retinoic acid binding protein isolated from the lumen of the rat epididymis~ERABP! is a member of the lipocalin
superfamily. ERABP binds both the all-trans and 9-cis isomers of retinoic acid, as well as the synthetic retinoid
~E!-4-@2-~5,6,7,8!-tetrahydro-5,5,8,8-tetramethyl-2 napthalenyl-1 propenyl#-benzoic acid~TTNPB!, a structural analog
of all-trans retinoic acid. The structure of ERABP with a mixture of all-trans and 9-cis retinoic acid has previously been
reported. To elucidate any structural differences in the protein when bound to the all-trans and 9-cis isomers, the
structures of all-trans retinoic acid–ERABP and 9-cis retinoic acid ERABP were determined. Our results indicate that
the all-trans isomer of retinoic acid adopts an 8-cis structure in the binding cavity with no concomitant conformational
change in the protein. The structure of TTNPB-ERABP is also reported herein. To accommodate this all-trans analog,
which cannot readily adopt a cis-like structure, alternative positioning of critical binding site side chains is required.
Consequently, both protein and ligand adaption are observed in the formation of the various holo-proteins.
Keywords: binding protein; retinoic acid; X-ray structure
It has long been known that retinol plays an important role in male
fertility. In the early 1960s, it was found that male rats raised on a
retinol-free diet supplemented with retinoic acid were blind and
sterile but “otherwise healthy.” The simplest interpretation of this
observation was that it is retinol and not retinoic acid~which
cannot be reduced in vivo! that is required for male fertility. How-
ever, retinoic acid may play a role in spermatogenesis or sperm
maturation as well, and its inability to substitute for retinol may be
due to the fact that retinoic acid cannot cross the blood-testis
barrier. Instead, retinol is converted to retinoic acid in situ. In the
testis, spermatogonia undergo a series of transformations and sub-
sequently emerge as spermatozoa. Upon exiting the testis, the sper-
matozoa must traverse the epididymis and in transit through the
organ acquire the ability to fertilize an egg. Both cellular and
extracellular retinoic acid binding proteins are abundant in testis
and epididymis~see Ong et al., 1994!. Furthermore, high levels of
the transcripts for the retinoic acid receptors~RAR!-a and -b have
been observed in the epididymis and testis~e.g., Kim & Griswold,
1990; Wan et al., 1992!.
A retinoic acid binding protein abundant in the lumen of the
epididymis ~epididymal retinoic acid binding protein~ERABP!!
that binds both 9-cis and all-trans retinoic acid is a member of the
lipocalin superfamily. The crystal structure of the protein has been
described in the absence and presence of the ligand~Newcomer,
1993; Newcomer et al., 1993!. The original crystals of the holo-
protein were prepared with all-trans retinoic acid, however, during
the time required for the growth of crystals significant amounts of
9-cis retinoic acid can accumulate. The clear sickle shape of the
ligand electron density led the authors to check for the presence of
9-cis retinoic acid in the crystals and the ability of the protein to
bind 9-cis retinoic acid. The crystal was found to contain a mixture
of the 9-cis and all-trans isomers and hence any conformational
differences between the protein ligand complexes could not be
discerned~Newcomer et al., 1993!. To elucidate any such confor-
mational differences, we have prepared crystals of ERABP with
9-cis and all-trans retinoic acid with highly purified isomers under
conditions in which isomerization is minimized.
Synthetic retinoids have been developed as possible therapeutic
agents, as retinoic acid based compounds have been shown to be
effective in oncology and dermatology. One early such retinoic
acid analog is~E!-4-@2-~5,6,7,8!-tetrahydro-5,5,8,8-tetramethyl-2-
napthalenyl!-1-propenyl#-benzoic acid~TTNPB!, which has been
shown to be 80% as effective as retinoic acid in RAR activation
assays~Manglesdorf et al., 1990!. TTNPB was developed as a
conformationally restricted analog of the all-trans isomer, yet TT-
NPB competes well with all-trans retinoic acid for binding to
ERABP, despite the fact that the X-ray structure clearly revealed a
binding site that appears more complementary in shape to the 9-cis
isomer of the ligand, and one in which all-trans retinoic acid must
adopt a cis-like conformation in order to bind. The all-trans and
9-cis isomers of retinoic acid when bound to ERABP have their
trimethylcyclohexenyl rings and carboxylates situated in the same
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volumes of the protein binding site. The carboxylates participate in
a charged cluster, which is critical for ligand recognition, as retinol
or retinal do not bind to ERABP. It is this positioning of the
carboxylate that necessitates a rotation about the C8-C9 bond of
the isoprene tail of the all-trans isomer. Since conformationally
restricted TTNPB cannot adopt a cis-like conformation and posi-
tion its carboxylate for the critical protein:ligand interaction ob-
served with the natural ligands, we extended our studies to include
the structure determination of ERABP with TTNPB.
We report here the structures of ERABP with all-trans retinoic
acid, 9-cis retinoic acid, and TTNPB, as well as the 1.65 Å native
structure with dimethyl sulfoxide~DMSO! bound in the hydro-
phobic binding cavity. Our results indicate that although the pro-
tein bound conformations of the all-trans and 9-cis isomers of
retinoic acid are superimposeable and the protein itself displays no
conformational differences between the two holo-forms, the con-
formationally restricted all-trans retinoic acid analog TTNPB is
shifted relative to the retinoic acid isomers in the binding cavity,
and the placement of the TTNPB carboxylate requires an alterna-
tive positioning of amino acid side chains.
Results and discussion
ERABP is a member of the lipocalin superfamily and thus displays
the structural framework common to the lipocalins: an eight-
stranded up-and-downb-barrel with a carboxy-terminala-helix.
The two layers ofb-sheet that form the barrel stack orthogonally
and one end of the open barrel is sealed by amino acid side chains
from the amino-terminus; the opposite end of the barrel provides
access to an internal binding cavity, which is hydrophobic and
complementary in shape to the ligand. Lipocalins, which bind
retinol, retinal~Lepperdinger et al., 1996!, and retinoic acid, have
been identified. Structures for retinol~Cowan et al., 1990; Zanotti
et al., 1993! and retinoic acid binding lipocalins~Newcomer, 1993!
have been described.
Comparison of the holo- and apo-ERABP structures
It was previously observed that crystals of apo-ERABP are signif-
icantly better in quality than crystals of the holo-protein. There-
fore, to obtain a high resolution structure of ERABP with ligand~s!,
the ligand solubilized in DMSO was added to the mother liquor in
which the apo-crystals were harvested. Although the crystal pack-
ing is relatively tight~Vm5 2.1 Å30D!, the binding site is open and
the access relatively unobstructed. However, a difference Fourier
calculated with data collected on crystals soaked at least one week
in TTNPB revealed no electron density for the retinoid. Refine-
ment of the structure to 1.65 Å resolution did, however, reveal a
molecule of the DMSO carrier positioned in the binding cavity.
The inability to diffuse ligand into the apo-ERABP crystals neces-
sitated the preparation of holo-crystals by cocrystallization.
Difference Fouriers calculated with X-ray data from the cocrys-
tallized crystals prepared with all-trans and 9-cis retinoic acid as
well as TTNPB had clear ligand density. A representative simu-
lated annealing omit map is given in Figure 1.
For the sake of simplicity, the comparison of the molecules is
with monomer “B,” as the ligand density for B is markedly better
for all but the TTNPB cocrystal structure.~An explanation for this
observation is given below.! An overlay of all four structures is
given in Figure 2A. Note that the bulk of the conformational
differences between the structures is limited to the loop regions.
These regions in all the structures are mobile, as inferred from the
fact that the temperature factors in these regions are significantly
higher than the average overall temperature factor. The all-trans,
9-cis, and TTNPB cocrystal structures superimpose onto the
apo~DMSO! protein well with root-mean-square deviations
~RMSDs! of 0.47, 0.43, and 0.66 Å, respectively. The larger de-
viation for the TTNPB structure is a consequence of the fact that
the placement of this ligand in the binding site requires that those
side chains at the carboxylate end of the binding site must repo-
sition. Furthermore, the bulkier ring region appears to require mi-
nor adjustments in the aromatic cluster at the ring end of the
binding site. In contrast, no significant conformational differences
in protein structure are observed when comparing the all-trans and
9-cis retinoic acid holo structures~RMSD 0.21 Å!. It is the con-
formational flexibility of the ligand that allows both isomers to
bind without concomitant structural differences in the protein.
Details of the binding site
As mentioned above, the structure of ERABP with a mixture of
all-trans and 9-cis isomers of retinoic acid has previously been
Fig. 1. Simulated annealing omit map for all-trans retinoic acid ERABP at 2.1 Å resolutions contoured at 1s.
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described. In that structure the ligand is clearly sickle shaped, and
all-trans retinoic acid adopts an 8-cis structure~where the C7-C8-
C9-C10 torsion angle is equal to 0! in the binding cavity. The
binding site of ERABP is complementary to the amphipathic li-
gand in both shape and chemical nature, and largely excludes
water, in contrast to what is described for the retinoic acid binding
site of the cellular retinoic acid binding protein~Kleywegt et al.,
1994!. An aromatic cluster at the trimethylcyclohexenyl ring end
of the ligand encircles the ligand~Fig. 2B!, the isoprene tail is
surrounded by hydrophobic amino acids, and the carboxylate tail is
neutralized in a web of charged amino acids surrounding the en-
trance to the binding cavity~Fig. 2C!. Interestingly, when crystals
are prepared with 9-cis retinoic acid and all-trans retinoic, it is
crystals of the former that are of lesser quality. However, despite
the relatively poor quality of the 9-cis data, it is clear that the
ligands interact with the protein in an equivalent fashion, despite
the fact that the structures of the free ligands are not superimpo-
seable and the fact that all-trans retinoic must adopt a cis-like
conformation.
In contrast, the all-trans retinoic acid analog TTNPB is shifted
in its placement in the binding site, presumably a result of the
bulkier ring moiety and the additional conformational restraints of
Fig. 2. Superpositions of apo~green!, all trans retinoic acid~red!, 9-cis retinoic acid~black!, and TTNPB~blue! ERABP structures.
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the “tail” region. The carboxylate of the TTNPB is thus positioned
;3.5 Å from the carboxylate of the all-trans and 9-cis structures,
and the amino acids of the protein that form the charged pair web
at the carboxylate end of the amphipathic binding site are alterna-
tively positioned to neutralize the TTNPB carboxylate. In Fig-
ure 3, overlays of the protein bound 9-cis and all-trans isomers as
well as the all-trans isomer and TTNPB are provided. It is clear
from this figure that neither the “ring” or “tail” of TTNPB super-
impose with the corresponding moieties of the natural ligand that
TTNPB mimics.
Conformational differences observed between
the two molecules of the asymmetric unit
ERABP crystallizes with two molecules in the asymmetric unit. In
Figure 4 the molecules “A” and “B” from the four structures~apo,
all-trans and 9-cis retinoic acid, and TTNPB ERABP! are super-
imposed. Note that loops at the open end of the barrel in molecule
“A” are displaced from those in molecules “B.” An important
protein ligand interaction, which involves Arg80 and the carbox-
ylate of the 9-cis and all-trans isomers of retinoic acid, is absent in
molecule A, as crystal packing contacts do not allow placement of
this loop as it is positioned in molecule B. This observation is
consistent with the fact that ligand density in molecule A for the
9-cis and all-trans isomers of retinoic acid is not as well defined as
that in molecule B. This disparity in occupancy is not observed for
the TTNPB-ERABP structure because the ligand itself, due to its
conformational restraints, requires alternative positioning of Arg80.
Despite the protein conformational difference, TTNPB binds as
well as the biological ligands. When incubated with equimolar
amounts of TTNPB and either all-trans or 9-cis retinoic acid,;60%
of the ligand extracted from the protein is TTNPB~Newcomer
et al., 1993!.
A role for Arg80 in protein ligand recognition has been verified
by the results of site-directed mutagenesis experiments. Sundaram
et al. ~1998! prepared the E63I, R80I double mutant of ERABP.
Unlike the wild-type protein, the double mutant ERABP binds
retinol, retinal, and retinoic acid. TheKd for retinoic acid is roughly
wice that for wild-type ERABP. The authors suggest that the
modest reduction in affinity for retinoic acid of the double mutant
indicates that the primary interactions responsible for ligand affin-
ity are the hydrophobic contacts.
Comparison to other binding sites for
all-trans and 9-cis retinoic acid
The retinoic acid nuclear receptor RAR binds both all-trans and
9-cis retinoic acid, while the retinoid X receptor~RXR! binds only
9-cis retinoic acid. In the structures of RAR-g with 9-cis and
all-trans isomers of retinoic acid, the ligands also are superimpo-
seable~Klaholz et al., 1998!. In this case, a difference in the
ring-tail dihedral angle of the isomers~the angles are 45 and 268
for the all-trans and 9-cis isomers, respectively, for the C5-C6-
C7-C8 dihedral! allows for the two ligands to assume the same
overall shape and one in which the isoprene tail of the all-trans
isomer is fully elongated. The structure of RAR with a synthetic
retinoic acid analog was also reported. Like TTNPB, this analog
has a tetrahydro-tetramethyl-napthalenyl~TTN! moiety on one
end, and benzoic acid on the carboxylate end. In the holo structure,
the tetramethyl portion of the TTN moiety is positioned as one
might predict in the volume occupied by the trimethylcyclohex-
enyl ring of retinoic acid. The carboxylate of the analog super-
imposes with the carboxylate of the natural ligands, the 9-cis and
all-trans isomers of retinoic acid. The binding site accommodates
all-trans retinoic acid without the substantial ligand conforma-
tional change observed for ERABP, and consequently the confor-
mationally restricted synthetic analog can position in the binding
site such that both ring and tail ends superimpose with all-trans
retinoic acid. This positioning of both ends of the ligand is crucial
for the nuclear receptors, in which the ligand must be fully encap-
sulated to invoke the conformational change that is required for the
activation function of the receptors~Bourguet et al., 1995; Renaud
et al., 1995!. Similarly, in the cellular retinoic acid binding pro-
teins, all-trans retinoic acid binds in an extended conformation and
ligand analogs utilize the same protein–ligand interactions ob-
served for the natural ligand~Kleywegt et al., 1994!. In ERABP,
however, the carboxylate end of the ligand binding cavity is rela-
tively exposed, and only minor side-chain movement is necessary
to accommodate a repositioning of the carboxylate. However, this
option is not used for the binding of the all-trans isomer retinoic
acid: the protein invokes a conformational change in the ligand.
Concluding remarks
In solution retinoic acid is a relatively well-constrained amphi-
pathic ligand: the trimethylcyclohexenyl ring at one end and car-
boxylate at the opposite end are fixed in their spatial relationship,
a consequence of the conjugated double bond system of the iso-
prene tail. Yet, protein bound retinoic acid can assume alternative
conformations. Rotation about the ring-tail dihedral is necessary to
relieve unfavorable intramolecular interactions, and protein bound
Fig. 3. Superpositions of protein bound ligands.A: All-trans retinoic acid
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retinol, and retinoic acid ring-tail dihedrals vary, presumably a
result of the intramolecular interactions and the geometric con-
straints of the different binding sites. Similarly, rotation within the
isoprene tail is possible if binding site geometry dictates. And
although the synthesis of synthetic analogs, which are conforma-
tionally restricted, may provide information about the protein bind-
ing site in the absence of protein structure information, it is apparent
from the results of these studies that the interpretation of structure
function relationships can be complicated by the fact that both




ERABP was purified as previously described~Newcomer & Ong,
1990!. Crystals of the apo-protein were grown by hanging drop-
vapor diffusion. Equal volumes of protein~at 6–8 mg0mL! and
well solution were suspended above a well solution of 40% satu-
rated ammonium sulfate, 10 mM Tris-HCl~pH 8.0!, 10–12% glyc-
erol, 2.5 mM EDTA at room temperature. Initial attempts to soak
large apo-crystals in mother liquor to which retinoid dissolved in
DMSO were added resulted in crystals in which DMSO, but not
retinoid, was clearly revealed in the binding cavity. Holo-crystals
were then grown from preparations of protein~4 mg0mL! to which
ligand was added~dissolved in DMSO!. These crystals appear at a
significantly lower concentration of ammonium sulfate~31%!. Al-
though distinct in their morphologies, apo- and holo-crystals are
isomorphous. The apparent difference in unit cell dimensions given
in Table 1 is simply a result of alternative indexing, specifically the
arbitrary assignment of the direction of theb-axis. Ligand isom-
erization was minimized by limiting exposure of the crystallization
experiments to light. In addition, microseeding reduced the time
necessary for crystal growth.
Data collection
Data were collected at room temperature on San Diego Multiwire
Area Detectors mounted on a Rigaku RU-200 rotating anode. A
single crystal mounted in a glass capillary was required for each of
the four data sets. Statistics are provided in Table 1.
Fig. 4. Superposition of molecules “A”~grey! and “B” ~black! for all four structures. The side chains of Arg80 and Lys85 are depicted,
as well as ligand for the all-trans retinoic acid holo structure.
Table 1. Data collection statistics
Apo TTNPB
All-trans
retinoic acid 9-cis-retinoic acid
Unit cell a 5 37.37 Å 39.89 39.86 40.08
b 5 58.71 59.06 59.14 59.64
c 5 66.72 65.31 65.18 65.93
b 5 109.218 105.68 105.68 105.98
Resolution 1.64 Å 2.0 2.15 2.8
Rsym 8.0 ~35.1! 8.1 ~34.7! 8.7 ~30.9! 11.3 ~40.4!
I0s 9.9 ~1.5! 7.9 ~2.0! 7.9 ~2.1! 8.6 ~2.1!
Total number observations 104,061 49,644 34,523 22,672
Unique reflections 30,574 18,098 15,045 7,410
Completeness of data 87~83! 91 ~86! 92 ~90! 98 ~95!
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Structure determinations
The 2.1 Å resolution structure of ERABP served as the starting
model for the four structures~with an appropriate rotation applied
to the model for those crystal data sets indexed withb 5 1058!. An
apo-protein crystal soaked in TTNPB dissolved in DMSO revealed
no electron density for the retinoic acid analog, but had clear
density for the DMSO in molecule B. The structure was refined to
1.65 Å resolution after an initial simulated annealing at 1,000 K by
successive cycles of positional refinement in X-PLOR~Brünger,
1993! and interpretation of 2Fo 2 Fc and difference maps with the
program O~Jones et al., 1991!. Approximately 10% of the reflec-
tion data was omitted from the refinements and monitored through-
out by calculation of theRfree ~Brünger, 1992!. The structures of
the protein with all-trans retinoic acid, 9-cis retinoic acid, and
TTNPB were refined similarly. IndividualB-factors were refined
for the native, all-trans retinoic acid, and TTNPB structures. For
the 9-cis retinoic acid structure, one main chain and one side chain
B per residue was refined. Ligand fits were confirmed by inspec-
tion of simulated annealing omit maps. The final refinement sta-
tistics for the four structures are given in Table 2.
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